According to our knowledge, this is the largest NMA of included studies evaluating the effectiveness and security of PD‐1 inhibitors plus chemotherapy and PD‐L1 inhibitors plus chemotherapy in the initial therapy of patients with ES‐SCLC. The gene discussed is CD274; the disease is small cell lung carcinoma.